JPMorgan Chase & Co. Raises Stock Holdings in Heron Therapeutics, Inc. (NASDAQ:HRTX)

JPMorgan Chase & Co. increased its position in Heron Therapeutics, Inc. (NASDAQ:HRTX) by 295.8% in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 206,711 shares of the biotechnology company’s stock after acquiring an additional 154,487 shares during the quarter. JPMorgan Chase & Co.’s holdings in Heron Therapeutics were worth $411,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the stock. Sei Investments Co. purchased a new position in shares of Heron Therapeutics during the second quarter worth about $44,000. Squarepoint Ops LLC grew its stake in Heron Therapeutics by 369.0% in the second quarter. Squarepoint Ops LLC now owns 363,700 shares of the biotechnology company’s stock worth $1,273,000 after purchasing an additional 286,160 shares during the period. AQR Capital Management LLC grew its stake in shares of Heron Therapeutics by 1,460.9% in the 2nd quarter. AQR Capital Management LLC now owns 607,135 shares of the biotechnology company’s stock worth $2,125,000 after buying an additional 568,238 shares during the last quarter. The Manufacturers Life Insurance Company increased its holdings in shares of Heron Therapeutics by 16.0% during the second quarter. The Manufacturers Life Insurance Company now owns 45,771 shares of the biotechnology company’s stock valued at $160,000 after acquiring an additional 6,328 shares in the last quarter. Finally, B. Riley Wealth Advisors Inc. bought a new position in shares of Heron Therapeutics in the second quarter worth approximately $41,000. 80.01% of the stock is owned by institutional investors.

Heron Therapeutics Stock Down 7.2 %

HRTX stock opened at $1.67 on Thursday. Heron Therapeutics, Inc. has a twelve month low of $1.04 and a twelve month high of $3.93. The stock has a market capitalization of $254.01 million, a price-to-earnings ratio of -9.28 and a beta of 1.60. The firm’s fifty day simple moving average is $1.54 and its two-hundred day simple moving average is $1.88.

Heron Therapeutics (NASDAQ:HRTX) last announced its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($0.03) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.03). The company had revenue of $32.81 million for the quarter, compared to the consensus estimate of $36.40 million. During the same quarter in the previous year, the business earned ($0.17) EPS. As a group, equities research analysts expect that Heron Therapeutics, Inc. will post -0.13 EPS for the current year.

Analyst Ratings Changes

HRTX has been the topic of a number of recent research reports. Needham & Company LLC reissued a “buy” rating and issued a $4.00 target price on shares of Heron Therapeutics in a report on Wednesday, December 4th. StockNews.com lowered Heron Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.